and prescription drugs
Professional content for our medical and pharmaceutical visitors. The information in this section is for healthcare specialists only!Learn more
Our products are available in 65 countriesClick here to learn more
Egis activities extend to every field of the pharmaceutical value chainClick here to learn more
Egis is an innovation-oriented generic pharma company, one of the regional industry leaders.Click here to learn more
The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.
In close cooperation with our employees, we're currently working on redesigning our protective clothing. Though the project is still in progress, our collaboration was already acknowledged: we were awarded the Healthy Workplaces Good Practice Award, so we can move on to the next round organized for EU countries.
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer and better structured cooperation than before. Their common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.
New Year is a time of miracles and cherished wishes, it is essentially about and for children. Therefore, EGIS-RUS decided to give them a charity Christmas Tree “Chain of Good”. On December 21, 2019, EGIS-RUS’ office opened its doors for the children of the employees and young guests from the orphanage in Moscow.
Our portfolio consists of 629 products. Our main focus lies on treating diseases of the cardiovascular and central nervous system.Learn more about our products